Guardant Health Introduces Nearly a Dozen Groundbreaking Smart Liquid Biopsy Applications for Guardant360 Liquid Test
Some of the groundbreaking new applications for the Guardant360 Liquid test will allow healthcare providers to do the following in order to improve patient outcomes:
Confirm no actionable mutations in lung and colorectal cancers—helping fast-track patients to treatment without extra testing.
Identify the origin of cancers when the primary site is unknown, guiding better diagnosis and therapy.
Classify breast ER/PR/HER2 status and lung cancer histology subtypes with high precision by interpreting tumor-specific methylation signatures, enhancing standard testing methods.
Use pharmacogenomics to identify genetic variations vital for safe and effective use of common anti-cancer therapies, including those with FDA black box labeling.
Detect human papillomavirus (HPV) and Epstein-Barr (EBV), which influence prognosis and treatment plans in certain cancers.
Determine Homologous Recombination Deficiency (HRD) status to inform use of specific therapies like PARP inhibitors and platinum-based chemotherapy.
Use Human Leukocyte Antigen (HLA) genotyping as a biomarker to inform therapy selection and identify clinical trial opportunities.
'For the first time ever, we're able to reveal vital details about a tumor – including its fundamental phenotype and biological behavior – from just a blood sample,' said Helmy Eltoukhy, Guardant Health chairman and co-CEO. 'This gives healthcare providers the insights they need about a patient's cancer to make smarter treatment decisions, even when they can't access tumor tissue for analysis. The novel blood-based approach to comprehensive molecular profiling using our Guardant Infinity Smart Liquid Biopsy platform offers immense potential for future applications in cancer and beyond.'
Comprehensive biomarker testing through immunohistochemistry using tumor tissue has been the standard of care in oncology and helps ensure that clinicians don't miss critical information about a patient's specific type of cancer. The Guardant360 Liquid test now provides access to this extensive molecular profiling information through the blood by looking at the unique methylation signatures of specific tumor biomarkers.
Guardant liquid biopsy tests have been clinically validated in more than 1,000 publications and research abstracts. Test results for Guardant360 Liquid are available within seven days. For more information, visit the Guardant Health website.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health's liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operation' and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2024, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health's views as of any date subsequent to the date of this press release.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Why AppLovin Stock Was Gaining Today
Key Points Meta's revenue grew 22% in the second quarter, reflecting strong ad demand. That and Microsoft's strong quarter could bode well for AppLovin, as the high-growth stock is set to report Q2 earnings next week. Analysts are expecting earnings per share to double to $2.32. 10 stocks we like better than AppLovin › Shares of AppLovin (NASDAQ: APP), the fast-growing adtech company, were soaring today even as there was no news out on the company. Instead, the stock seemed to benefit from a wave of bullish sentiment for artificial intelligence (AI) and digital advertising stocks after strong reports from both Meta Platforms and Microsoft last night. As a result, AppLovin stock was up 8.2% as of 12:53 p.m. ET, while those two big tech stocks gained as well. AppLovin rides Meta's coattails Strong results from Meta in particular seemed to benefit AppLovin, as Meta's report showed off healthy demand in the digital advertising market. Revenue jumped 22% to $47.5 billion, and advertising made up 98% of its revenue, showing strong demand for ads on Facebook and Instagram. Meta credited AI improvements for driving both growth in ad impressions and an increase in the price per ad, reflecting increased demand and ROI. That trend, along with Microsoft's strong quarterly numbers, set off a wave of bullishness for stocks like AppLovin, which is high-priced and high-growth and offers exposure to both adtech and AI. In fact, AppLovin may be ahead of the curve in AI-driven advertising, as its AI-powered recommendation engine, Axon, has been a key source of growth for the company recently. What's next for AppLovin? As an expensive, high-growth stock, AppLovin tends to be volatile, and today's gains reflect an improved perception of its future growth ahead of its own earnings report on Aug. 6. Investors are expecting 13% revenue growth to $1.22 billion in the quarter, though that includes the sale of its mobile apps business. Excluding that, organic growth will be much stronger. On the bottom line, analysts expect earnings per share to essentially double to $2.32, a better reflection of the underlying growth in the business. The stock has the potential to pop again if it can beat those estimates. Do the experts think AppLovin is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did AppLovin make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,049% vs. just 182% for the S&P — that is beating the market by 867.25%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,629!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,098,838!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Jeremy Bowman has positions in AppLovin and Meta Platforms. The Motley Fool has positions in and recommends AppLovin, Meta Platforms, and Microsoft. The Motley Fool recommends the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool has a disclosure policy. Why AppLovin Stock Was Gaining Today was originally published by The Motley Fool 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
Yahoo
39 minutes ago
- Yahoo
Apple (AAPL) Poised for Major Cash Windfall Thanks to Big Beautiful Bill
Apple Inc. (NASDAQ:AAPL) is one of the . On July 30, Morgan Stanley reiterated the stock as 'Overweight.' According to the firm, One Big Beautiful Bill Act (OBBBA) will offer a significant boost to free cash flow (FCF) across the IT hardware sector. It noted that Apple is one of the big beneficiaries of the Big Beautiful bill. 'We estimate the One Big Beautiful Bill Act (OBBBA) can add 12% upside to our IT Hardware coverage FCF in 2025, and 5%, on average, annually, to our coverage over the next 4 years,' Through the bill, companies will be able to immediately deduct R&D and capital investment expenses from U.S. taxes. This will accelerate their tax savings and increase near-term cash flow. 'We estimate that over the next 4 years, the [One Big Beautiful Bill] will add a cumulative $20.3B of upside to our AAPL [free-cash flow] forecast, all else equal, which equates to an average annual FCF tailwind of 4%.' The firm projects the legislation will generate more than $12 billion in incremental cash flow for covered names over the next year, as well as $20 billion cumulatively over four years. 'This benefit is mostly about timing, as it pulls forward future tax savings rather than changing the long-term cash flow picture,' the analysts said. Apple is a technology company known for its consumer electronics, software, and services. While we acknowledge the potential of AAPL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Must-Watch AI Stocks on Wall Street and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
39 minutes ago
- Yahoo
Marvell (MRVL) Remains in AI Winners Camp as Morgan Stanley Nudges Target Higher
Marvell Technology, Inc. (NASDAQ:MRVL) is one of the . On July 30, Morgan Stanley analyst Joseph Moore raised the price target on the stock to $80.00 (from $73.00) while maintaining an 'Equal Weight' rating. 'Marvell is firmly in the AI winners camp, and sentiment has swung aggressively negative compared to a few months ago,' Moore wrote. 'We are more excited for their opportunity in optical, which brings higher margin and durability vs. their ASIC opportunity, which has disappointed.' An analyst studying a graph of a company's asset value and potential cash flow. Moore expects Marvell to benefit from strong AI demand in the coming year. 'While stock prices have moved higher, our conviction on AI spend durability in 2026 continues to grow.' Marvell Technology, Inc. (NASDAQ:MRVL) engages in the development and production of semiconductors, focusing heavily on data centers. While we acknowledge the potential of MRVL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 Must-Watch AI Stocks on Wall Street and Disclosure: None.
